tradingkey.logo
tradingkey.logo
Search

Immunic Inc

IMUX
Add to Watchlist
7.520USD
-0.270-3.47%
Close 11-13 16:00(ET)
102.57MMarket Cap
LossP/E TTM

About Immunic Inc Company

Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.

Immunic Inc Profile

Ticker SymbolIMUX
Company nameImmunic Inc
IPO dateApr 17, 2014
CEOVitt (Daniel)
Number of employees91
Security typeOrdinary Share
Fiscal year-endApr 17
Address1200 Avenue Of The Americas
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10036
Phone13322559818
Websitehttps://imux.com/
Ticker SymbolIMUX
IPO dateApr 17, 2014
CEOVitt (Daniel)

Company Executives of Immunic Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Daniel Vitt, Ph.D.
Dr. Daniel Vitt, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
39.19K
--
Dr. Joerg Neermann, Ph.D.
Dr. Joerg Neermann, Ph.D.
Independent Director
Independent Director
20.00K
--
Mr. Glenn Whaley, CPA
Mr. Glenn Whaley, CPA
Chief Financial Officer
Chief Financial Officer
9.55K
--
Dr. Duane D. Nash, M.D.
Dr. Duane D. Nash, M.D.
Director
Director
3.60K
+0.03%
Mr. Jason Tardio
Mr. Jason Tardio
President, Chief Operating Officer
President, Chief Operating Officer
1.25K
+0.08%
Dr. Simona Skerjanec, M.D.
Dr. Simona Skerjanec, M.D.
Independent Director
Independent Director
--
--
Mr. Thorvald (Thor) Nagel
Mr. Thorvald (Thor) Nagel
Independent Director
Independent Director
--
--
Mr. Werner Gladdines
Mr. Werner Gladdines
Chief Development Officer
Chief Development Officer
--
--
Mr. Jon Congleton
Mr. Jon Congleton
Independent Director
Independent Director
--
--
Ms. Jaa Roberson
Ms. Jaa Roberson
Chief People Officer
Chief People Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Daniel Vitt, Ph.D.
Dr. Daniel Vitt, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
39.19K
--
Dr. Joerg Neermann, Ph.D.
Dr. Joerg Neermann, Ph.D.
Independent Director
Independent Director
20.00K
--
Mr. Glenn Whaley, CPA
Mr. Glenn Whaley, CPA
Chief Financial Officer
Chief Financial Officer
9.55K
--
Dr. Duane D. Nash, M.D.
Dr. Duane D. Nash, M.D.
Director
Director
3.60K
+0.03%
Mr. Jason Tardio
Mr. Jason Tardio
President, Chief Operating Officer
President, Chief Operating Officer
1.25K
+0.08%
Dr. Simona Skerjanec, M.D.
Dr. Simona Skerjanec, M.D.
Independent Director
Independent Director
--
--

FAQs

Who are the top five shareholders of Immunic Inc?

The top five shareholders of Immunic Inc are: Dr. Daniel Vitt, Ph.D.

How many institutions hold shares of Immunic Inc (IMUX)?

As of 2026Q1, 137 institutions hold shares of Immunic Inc, with a combined market value of approximately 58.68M, accounting for 57.65% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 22270198.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.